Back to Search
Start Over
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- Source :
- The Journal of Clinical Endocrinology & Metabolism; August 2018, Vol. 103 Issue: 8 p2949-2957, 9p
- Publication Year :
- 2018
-
Abstract
- In ACTIVExtend, reductions in fracture risk and increases in BMD achieved with 18 months of abaloparatide for postmenopausal osteoporosis were sustained through 24 months of subsequent alendronate.
Details
- Language :
- English
- ISSN :
- 0021972X and 19457197
- Volume :
- 103
- Issue :
- 8
- Database :
- Supplemental Index
- Journal :
- The Journal of Clinical Endocrinology & Metabolism
- Publication Type :
- Periodical
- Accession number :
- ejs46434556
- Full Text :
- https://doi.org/10.1210/jc.2018-00163